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The proliferation and the differentiation of bone marrow 
progenitor cells are regulated by glycosylated hematopoietic 
hormones. The major site of hematopoiesis is in the stro!llal 
matrix of the bone marrow, with secondary sites in the spleen, 
kidney and thymus. The cellular components of the blood are 
thought to be derived from a pluripotent stem cell. The periph-
eral blood cells possess limited life spans in the circulatory 
system. Their numbers must be maintained under normal con-
ditions, and they must respond to the various environmental 
stresses placed upon the body. For example, the number of 
circulating leukocytes increases rapidly when an individual 
experiences severe infection12• 
Four of the major human myeloid growth factors will be 
discussed. Erythropoietin stimulates the production of red 
blood cells. Three colony-stimulating factors: Granulocyte 
colony-stimulating factor (G-CSF), granulocyte-macrophage 
colony stimulating factor (GM-CSF), and interleukin III (IL-
3), all influence the production and the maturation of the vari-
ous types of leukocytes. · 
These hormones have been biosynthetically isolated 
and cloned, by means of recombinant DNA technolo-
gy. The production of these factors in large quantities 
enables researchers to study their specific activities in 
on top of this feeder layer. When incubated, colonies of differ-
entiated white blood cells formed the second layer. Altering 
the contents of the feeder layer resulted in the formation of 
various types and numbers of colonies4 • 
The hematopoietic proteins were initially purified. In gen-
eral, their amino-acid sequence was used to construct eDNA 
probes. These probes were used to isolate the desired gene 
from the human DNA library. The recombinant DNA was 
cloned and inserted into mammalian or bacterial vectors, 
along with various enhancers or promoters designed to ampli-
fy the expression of the gene for the large scale production of 
the hormone. The successful utilization of recombinant DNA 
technology allowed for extensive experimentation with these 
factors in clinical trials. 
Erythropoietin was first isolated and purified from the 
urine of a patient with aplastic anemia'. The amino acid 
sequence was obtained and used to construct a DNA probe. 
This probe was used to identify the corresponding eDNA, 
which was then placed into mammalian cells. Mammalian 
METHODS FOR CLONING AND EXPRESSING 
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great detail and to analyze their therapeutic relevance. 
Clinical trials are currently being conducted to further 
elucidate their potential for increasing the numbers and 
the activities of the various blood cells. 
Identify the protein 
from human urine 
Characterize the protein Develop an assay to 
identify the protein 
The hematopoietins 
The hematopoietic proteins were first identified and 
purified from a variety of sources. In the late 1960s, the 
colony-stimulating factors were identified using cell-
culture colony-formation assays. These assays consist-
ed of 2 layers placed in a small laboratory dish. The 
first layer on the bottom of the dish, the "feeder layer," 
was comprised of various types of white blood cells in 
a semisolid medium. Bone marrow cells were placed 
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FIGURE 1: This figure outlines the steps utilized to clone and to express the 
gene for erythropoietin. Erythropoietin was the first of the hematopoietic 
growth factors to be manufactured biosynthetically. The form of erythropoietin 
used in clinical trials is produced only in mammalian cells. 
(Continued on page 128) >-
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HUMAN HEMATOPOIETIC( Continued from page 126) 
cells were utilized as the host cell for erythropoietin because 
of the inability of bacterial and yeast cells to perform the nec-
essary glycosylation steps in producing the biologically active 
form of the recombinant gene. The biosynthetically produced 
erythropoietin used in clinical trials is identical to the original, 
purified, urinary form. 
The eDNA for G-CSF was developed using a structural 
approach. The natural hematopoietin was first purified from 
human cell lines and from normal placentae'. These purified 
factors were subjected to structural analysis and the resultant 
amino-acid sequence was used to construct the nucleotide 
sequence of different regions of DNA. Hybridization probes 
were constructed to select the G-CSF eDNA from the human 
DNA library to isolate the gene2• The isolated eDNA sequence 
was inserted into E. coli and also into mammalian cells to pro-
duce the functional hormone. The nonglycosylated form of G-
CSF is used in clinical trials. 
The trace physiological quantities of GM-CSF present in 
its natural form made purification difficult. Therefore, a dif-
ferent strategy was employed for the identification and the 
production of GM -CSF. HTL V-II transformed T -lymphoblast 
cell lines induced the production of GM-CSF and other regu-
latory hormones. The GM-CSF was partially purified. 
However, the limited yield of the natural protein made 
sequencing of the protein difficult. Therefore eDNA clones 
were transiently expressed in COS-1 (monkey) cells to con-
struct eDNA libraries of approximately 300 recombinants 14• 
These libraries were tested to see if they induced the secretion 
of GM-CSF in various assays. 
The expression of GM-CSF mRNA in various cells such as 
lectin-stimulated periph-
eral blood lymphocytes, 
available facilitated the sequencing of the gene. 
Commercially, GM-CSF is produced in 3 different expression 
vectors: Mammalian cells, yeast cells, and bacterial cells 
(E.coliY These 3 vectors produce different levels of glycosy-
lation as compared to the natural protein. 
The eDNA for IL-3 was made through methods similar to 
those used to produce GM-CSF. IL-3 was the most difficult of 
the human growth factors to be isolated2• The IL-3 was puri-
fied in activated T-cells. The eDNA of a gibbon T-cell line 
encoding a multilineage CSF believed to be similar to IL-3 
was used as a hybridization probe to identify the human 
gene2•3• The direct functional analysis of the products of eDNA 
clones introduced into mammalian cells in the appropriate 
expression vector was a novel approach to identify and to pro-
liferate the hematopoietin. 
Signal transduction 
The mechanisms by which the hematopoietic growth fac-
tors affect their target cell have not yet been clearly delineat-
ed. Each growth factor binds to one specific receptor on the 
target cell surface8•12• The method and the prevalence of bind-
ing suggests that the individual receptors may affect the shape 
and, therefore, the ability of other receptors to bind to their 
specific factor. The synergistic effects of the various growth 
factors involve the interactions between the receptors and the 
growth factors bound to them8• The receptors may be activated 
transiently and may activate other growth proteins or sec-
ondary messengers such as cAMP or cGMP, depending on the 
mechanism of signal transduction in the stimulatory 
pathway6•9 • The control of hematopoiesis lies in the proper 
identification of the cell 
surface receptors and 
and some mature T -cell 
lines led to the further 
isolation of GM-CSF 
clones from the eDNA 
libraries' 4 • The natural 
GM-CSF was purified, 
using column chromatog-
raphy and 2 reversed-
METHODS FOR CLONING AND EXPRESSING 
THE RECOMBINANT HUMAN GM-CSF 
their relationships to the 
other receptors during 
hematopoietic differentia-
tion. In order to maintain 
normal growth as well as 
to promote rapid respons-
phase high-performance 
liquid chromatography 
(HPLC) steps. The 
recombinant GM-CSF 
was produced in large 
quantities using DNA 
transfection. Introducing 
the recombinant DNA 
into COS-1 cells allowed 
for production of recom-
binant GM-CSF, which 
also aided in the purifica-
tion process. The recom-
binant protein showed no 
difference in specific 
activity as compared 
with the natural protein. 
The large amounts of the 
recombinant protein 
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FIGURE 2: This figure outlines the steps utilized to clone and to express the 
gene for GM-CSF. IL-3 was cloned and expressed using similar methods. The 
trace quantities of these hormones caused difficulty in the large scale produc-
tion of the genes. However, recombinant DNA technology has made it possible 
to yield large quantities of these hormones. This allowed for research into the 
clinical applications of these two hematopoietic hormones. 
es to environmental 
stresses, the cascading 
events which initiate the 
proliferation and the dif-
ferentiation of the 
pluripotent stem cell must 
be identified. The make-
up of the receptors for 
erythropoietin, IL-3, GM-
CSF, and G-CSF have not 
yet been constructed. 
Because of the synergistic 
effects of the hematopoi-
etic hormones, it has been 
difficult to isolate or to 
identify the receptors. 
The receptor structures 
are expected to be as 
diverse as the structures 
of the hormones them-
selves9• 
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first used in patients with renal failure, a con-
dition associated with a decrease in erythro-
poietin production and marrow sensitivity. 
Anemia associated with a decrease in the num-
ber of red blood cells often accompanies dialy-
sis, and this is a result of the low levels of ery-
thropoietin and the increase of inhibitors and 
toxins. Recombinant erythropoietin adminis-
tration has been shown to increase the ery-
throid lineage, stimulating a dose-dependent 
rise in hematocrit levels. This has led to sub-
jective improvement in sleeping and waking 
patterns, exercise capability, energy, appetite, 
and libido1• The side effects of erythropoietin 
were controlled by regulating the rise of hema-
tocrit levels to 6% per month1• Hypertension 
may occur as a result of the increase in blood 
volume or in blood viscosity and must be 
closely monitored. 
Anemias associated with decreased levels 
of erythropoietin are expected to benefit from 
erythropoietin therapy. However, reports have 
shown that anemias associated with normal or 
high serum erythropoietin levels also show 
improvement in response to erythropoietin 
therapy 1• Patients with severe anemia or 
rheumatoid arthritis, for whom transfusions 
are contraindicated, may benefit from erythro-
poietin treatments1• 
Anemias accompanying various forms of 
therapy can also be treated with synthetic ery-
thropoietin. For example, zidovudine (AZT) 
treatment in AIDS patients causes anemia1• 
Simultaneous administration of erythropoietin 
has been successful in combating the anemia 
in patients receiving AZT unless the serum 
FIGURE 3: This figure provides an overview of hematopoiesis. The primary uncommit-
ted progenitor cell is the pluripotent stem cell. A cell closely related to this cell is the 
CFU-BLAST, a multipotent cell identified using the CFU-blast colony assay'. The first 
step in the differentiation of the stem cell is a division into two major cell lineages. The 
growth of the lymphoid cells and the myeloid cells (CFU-GEMM) are influenced by the 
various hematopoietic hormones. The various progenitor cells were identified in vitro as 
CFU-GEMM (colony-forming unit, granulocyte-erythrocyte-monocyte-megakaryocyte); 
BFU-E (burst-forming unit-erythroid); CFU-MEG (CFU-megakaryocyte); CFU-Eo (CFU-
eosinophil); CFU-E (CFU-erythroid); and CFU-GM (CFU-granulocyte-monocyte). 
erythropoietin levels were greater than 500 mu 
per milliliter before therapy 1• This would 
allow for adequate dosage and duration of 
zidovudine treatment in patients with AIDS. 
Erythropoietin also may be used on surgi-
cal patients, reducing the need for transfusion. 
Theoretically, the increase of erythrocyte pro-
duction by erythropoietin will improve the 
patient's ability to recover from red-cell deple-
Erythropoietin 
Erythropoietin regulates the production of red blood cells. 
It is produced in the peri tubular cells of the kidneys, circulated 
via the plasma and excreted in the urine. Renal production of 
erythropoietin is directly proportional to hypoxemia. 
Erythropoietin was the first hematopoietic growth factor to be 
identified and cloned in mammalian cells. The gene for ery-
thropoietin is located on the long arm of chromosome 7 
(Table-1)1•3•11 • 
The recombinant hormone used in clinical trials is derived 
from mammalian cells, due to the patterns of glycosylation 
necessary for the activation of the protein. The hormone was 
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tion. Erythropoietin would need to be adminis-
tered before, during and after surgery. This 
would reduce the risk inherent in giving transfusions and per-
haps ultimately the risk of the surgical procedure itself4 • 
IL-3 
IL-3 stimulates the proliferation of stem cells and commit-
ted progenitors of multiple lineage cells. It is an early-acting 
factor that stimulates proliferation of an enormous range of 
cell types. Clinical trials with the administration of IL-3 have 
begun but the results of these trials have not yet been reported. 
IL-3 was first produced by Yang et al in cultured monkey 
cells7• The inducible cellular source of IL-3 is the T-lympho-
cyte. The gene for IL-3 is located on the long arm of chromo-
(Continued on page 131) >-
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HUMAN HEMATOPOIETIC (Continued from page 129) 
some 54.12·' 4 • The association between IL-3 and the other 
hematopoietic growth hormones located on this chromosome 
has not yet been determined. 
GM-CSF 
The first human GM-CSF eDNA was cloned and 
expressed in mammalian cells by Wong et al4•7• Along with 
IL-3, GM-CSF (a multipoietin) will target pluripotent cells 
and immature progenitor cells. It is not lineage specific, and it 
is required to be present throughout the process of differentia-
tion. The gene for GM-CSF is also located on chromosome 
54•12 • GM-CSF stimulates the growth of both granulocytic and 
monocytic colonies in a semisolid culture. GM-CSF has an 
early effect on myeloid development, and together with ery-
thropoietin (late acting promoter of erythroid development), 
induces the formation of colonies containing erythroid and 
megakaryocytic cells. 
GM-CSF also enhances the function of mature macro-
phages, eosinophils, and neutrophils. In various cells, it can 
cause increases in tumoricidal and phagocytic activity, intra-
cellular killing, ADCC, superoxide production, immunoglob-
ulin-mediated (opsonized) phagocytosis and chemotactic 
responsiveness (Handman and Burgess 1979; Lopez et al 
1983, 1986; Vadas et al 1983; Wei sbart et al 1986; 
Williamson and Brown 1987)1. GM-CSF also induces an 
increase in granulocyte aggregation in vitro (Amaout et al 
1986; Lopez et al1986). 
GM-CSF administration reduces the myelotoxic side-
effects of chemotherapy for sarcoma. GM-CSF increases the 
neutrophil count; this can shorten the interval between cycles 
of chemotherapy. However, the ability to complete the cycle 
is not known to improve the survival rate or the response rate 
of the patient' . 
In bone marrow transplants, both mammalian recombinant 
GM-CSF and recombinant GM-CSF produced from yeast 
were tested. Mammalian cell GM-CSF did not significantly 
reduce the number of days that the leukocyte count was below 
1,000/cubic millimeter. However, on the 14th day after treat-
ment, a higher leukocyte count showed up and the incidence 
of bacteremia was reduced. Yeast-produced GM-CSF, in con-
trast, showed a shorter period of neutropenia (14 days as com-
pared with 25 days in the control group); a decrease in the 
number of febrile days (6 days compared with 12 days); a 
decrease in the number of platelet units transfused (67 days 
compared with 84 days); and a reduction in the length of hos-
pital stay (29 days compared with 41 days)'. There was also a 
reduced period of pancytopenia and a reduction in the infec-
tious complications associated with autologous bone marrow 
transplants. However, it was not established whether there 
was also a decrease in the mortality rate of GM-CSF treated 
patients '·7• 
Aplastic anemia is caused by a decrease in the number of 
marrow stem-cells the result of an altered marrow microenvi-
ronment or immunologic disorder. GM-CSF improved the 
leukocyte count and bone marrow cellularity but with no 
increase in neutrophils . Therefore, the early progenitor cells 
affected may also require treatment with additional growth 
factors to be effective. However, these tests have not yet been 
conductedu. 
Continuous intravenous infusion with GM-CSF for 14 
(Continued)~ 
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PROPERTIES OF HUMAN COLONY-STIMULATING FACTORS 
Therefore, the advantage of the 
administration of GM-CSF is 
being studied in conjunction with 
treatment with Zidovudine. 
Although GM-CSF counteracts 
the negative side-effects of some 
treatments, it is not yet clear if this 
also leads to an improved outcome 
for the patient with AIDS 1•7• 
FACTOR MOLECULAR 
WEIGHT 
(kd) 
EPO 34-39 
G-CSF 18-22 
GM-CSF 14-30 
IL-3 47-90 
CHROMOSOME CELL 
LOCATION PRODUCER 
7qll-q22 Peri tubular 
cells of the 
of the kidney, 
Kupffer cells 
17q11.2-21 Monocytes, 
5q23-31 
bone marrow 
stromal cells 
T lymphocytes, 
endothelial 
cells, bone 
marrow stromal 
cells, 
fibroblasts 
5q23-31 T lymphocytes 
CELL 
STIMULATED 
late BFU-E, 
CFU-E, 
CFU-Meg 
CFU-G, 
HL60 
cell line 
CFU-GM, 
BFU-E, 
CFU-MIX, 
CFU-EO, 
CFU-Meg, 
Granulocytes, 
Monocytes, 
Eosinophils, 
KGI &HL60 
cell lines 
CFU-MIX, 
BFU-E, 
CFU-GM/G/M, 
CFU-EO, 
CFU-Meg 
CLINICAL 
APPLICATIONS 
renal failure, 
anemias, 
preoperative & 
postoperative 
patients, 
AIDS 
bone marrow 
transplants, 
chemotherapy, 
neutropenias 
bone marrow 
transplants, 
chemotherapy, 
myelodysplasia, 
anemias, 
neutropenias, 
AIDS 
11nknown 
G-CSF 
G-CSF is a late-acting factor 
that stimulates the growth of neu-
trophil colonies in vitro. G-CSF 
was first purified from human cell 
lines and placenta 1• This factor 
was isolated and cloned by Souza 
et al in E.coli4•7 • The inducible cel-
lular source of G-CSF are the 
monocytes and bone marrow stro-
mal cells. The gene for G-CSF has 
been located on the long arm of 
chromosome 174•12 • G-CSF also 
has a maturation-inducing effect 
and will act on mature effector 
cells to enhance their function. It 
TABLE 1: This table lists the various properties of 4 hematopoietic hormones, erythropoietin, G-CSF, 
GM-CSF, and IL-3. 
acts only on the neutrophil 
colonies to increase antibody-
dependent cell-mediated cytotoxi-
days in patients with pancytopenia due to myelodysplasia has 
demonstrated an increase in the total number of leukocytes (5 
to 70 fold), granulocytes (5 to 313 fold), eosinophils, mono-
cytes, and also a small increase in lymphocyte count. 
Maintenance therapy showed some multilineage effects. There 
was an increase in platelet and reticulocyte count, and an 
increase in hemoglobin concentration which caused a decrease 
in the necessity to transfuse red cell and platelets. However, 
the increase in platelet and erythrocyte count frequently did 
not occur; this was of minimal clinical importance1•7 • 
The most significant characteristic of AIDS in patients is 
the decrease in T4lymphocytes. The low levels and decreased 
functional abilities of neutrophils and monocytes in AIDS 
patients can be improved by the various treatments against the 
virus. However, Zidovudine (AZT) treatment has been shown 
to cause myelosuppression. In addition, antiretroviral, antimi-
crobial, or antitumor therapy used as therapy in AIDS patients 
can give rise to low blood counts. The use of GM-CSF and G-
CSF have resulted in an increase in neutrophils, bands, 
eosinophils, and a slight increase in monocytes. The dose-
dependent response to GM-CSF and G-CSF could benefit the 
patient's immune response and improve the hematologic toler-
ance to other drugs. These growth factors have also proven to 
be effective for long-term therapy, as shown by the absence of 
tachyphylaxis when given subcutaneously. 
GM-CSF alone does modulate HIV activity. Studies indi-
cate that there is an increase in HIV p24 antigen (viral specific 
protein) levels when patients are treated with GM-CSF alone. 
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city (ADCC) and to enhance their 
phagocytic capability. 
The nonglycosylated form of 
the recombinant hormone produced in bacterial cells is used in 
clinical trials. Similar to GM-CSF, G-CSF has also shown 
promising beneficial effects on chemotherapy. G-CSF reduces 
the myelotoxicity of chemotherapy, making the side-effects 
more tolerable. There is a reduction in the duration and the 
nadir of neutropenia after doxorubicin hydrochloride 
(Adriamycin), ifosfarnide-mesna and etoposide treatment. G-
CSF will increase the neutrophil count, reduce febrile 
episodes, and reduce the incidence of mucositis. However, 
only at very high doses will G-CSF increase monocyte or 
lymphocyte counts. 
The significant consequence of G-CSF treatment in con-
junction with chemotherapy in cancer patients was the partial 
mitigation of the myelosuppression. This permitted the com-
pletion of the cycle of chemotherapy without undue delay in 
patients being given chemotherapy for bladder cancer1• 
Myelosuppression was the cause for a lapse in chemotherapy 
in 70% of a control group who did not receive G-CSF 1• 
However, this did not improve the survival rate or response 
rate of the patients who were administered G-CSP·'. 
Treatment with G-CSF in bone-marrow transplant patients, 
as well as in patients with myelodysplasia, showed similar 
results as those treated with GM-CSF. The analysis of the 
advantage of using G-CSF or GM-CSF has not yet been fully 
explained, however. Further studies and clinical tests must be 
conducted before differences in the action of these 2 growth 
factors in such situations can be determinedl.7. 
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Idiopathic neutropenias are also being treated with G-CSF. 
For example, patients with Kostmann's Syndrome who have 
recurrent infections with considerable morbidity and mortality 
as a consequence, show improved neutrophil counts of 1,000 
cells per mm3 within 2 weeks after G-CSF administration. 
This level was sustained throughout continued therapy. The 
resolution of the preexisting chronic infection and a decrease 
in the number of subsequent re-infections also took place 
under treatment with G-CSP7 • 
In addition, human cyclic neutropenia, a rare disorder in 
which periodic decreases in the number of neutrophils in the 
bone marrow and the blood occur, when treated with G-CSF 
showed a reduction in the length of neutropenia. G-CSF 
reduced both the severity of the disease and the accompanying 
symptoms. However, it did not rid the patient of the disorder. 
G-CSF as treatment has shown encouraging results in 
acquired chronic neutropenias. Obviously, further clinical tri-
als and study are necessary to elucidate the potential benefits 
of administering G-CSP·7 • 
Conclusion 
Research in the last 10 years has provided the information 
necessary to clone and to express the hematopoietic hor-
mones. This has allowed for a wide range of clinical trials to 
determine the therapeutic benefits of these hormones in the 
treatment of various disorders. Erythropoietin increases the 
number of red cells in circulation. It has been utilized success-
fully in patients with renal disorders and anemias. In preopera-
tive and postoperative patients, erythropoietin has resulted in 
more rapid red cell recovery. Erythropoietin is also employed 
to combat the side effects of various therapies, most notably in 
AIDS. 
The colony-stimulating factors, IL-3, GM-CSF, and G-
CSF, increase the number of leukocytes in vitro. The synergis-
tic effects of these hormones requires extensive study in order 
to define the singular role each factor plays on the production 
of the desired cell types. Clinical trials are taking place to 
determine the effects of these factors when administered to 
patients with conditions involving decreased immune 
response as a result of low levels of circulating leukocytes. Of 
the 3 colony-stimulating factors discussed above, the least 
known for its therapeutic benefit is IL-3. 
GM-CSF has also been beneficial when used in conjunc-
tion with various treatments, such as chemotherapy and AZT, 
by increasing the number of circulating neutrophils and mono-
cytes. GM-CSF reduces the risk for both the donor and the 
recipient in bone marrow transplants. It resolves the anemias 
associated with a decrease in the marrow stem-cells, or it 
improves the marrow environment. It ameliorates the neu-
tropenia resulting from therapy for cancer. 
G-CSF has shown therapeutic benefits similar to GM-CSF. 
Bone-marrow transplants, myelodysplasia and neutropenias 
have been improved as indicated by increased numbers of 
neutrophils. In the treatment of the neutropenia caused by 
chemotherapy, G-CSF has shown advantages similar to those 
seen in the administration of GM-CSF. GM-CSF and G-CSF 
have shown similar results when utilized in clinical trials. The 
difference between the 2 growth factors has not yet been iden-
tified, further research and experimentation are needed to 
determine the advantage of one factor over the other. 
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The hematopoietic growth factors have the potential to 
enhance the quality of life in patients suffering from a broad 
range of illnesses and conditions. Defining the indications and 
the toxicities of these factors will be an area of enormous 
interest and importance in the years to come. 
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